Skip to content

Study · Non-randomized trial · n = 20 · 1984

6 results

Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults.

Grossman A, Savage MO, Lytras N, Preece MA, Sueiras-Diaz J, Coy DH, Rees LH, Besser GM

Clinical endocrinology1 Sept 1984Cited by 55 (Europe PMC)

PMID6236914 (opens in a new tab)DOI10.1111/j.1365-2265.1984.tb03477.x (opens in a new tab)PepBankPUB-06236914
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 20 children and young adults with GH deficiency, eight showed normal or only slightly subnormal peak serum GH responses to GHRH(1-40) or GHRH(1-29)NH2.

    In plain wordsIn 20 young people with low growth hormone, eight still had a normal or nearly normal growth hormone rise after GHRH.

    Peptide
    Sermorelin
    Outcome
    MixedPeak serum GH response in GH-deficient children and young adults
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In 20 children and young adults with growth hormone deficiency by conventional criteria, eight showed normal or only slightly subnormal peak serum GH responses to GHRH(1-40) or GHRH(1-29)NH2.
  2. 02HumanNon-randomized trialEfficacy outcome

    In normal subjects, GHRH(1-29)NH2 was equipotent to GHRH(1-40) in stimulating GH release.

    In plain wordsIn normal people, the shorter GHRH peptide worked as strongly as the longer GHRH(1-40) at stimulating growth hormone.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GH potency versus GHRH(1-40) in normal subjects
    Study

    n: not reported in source

    Comparator
    GHRH(1-40)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRH(1-29)NH2 is equipotent to GHRH(1-40)
    1 context sentence
    Summary · context
    Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal subjects, increasing doses of GHRH(1-29)NH2 from 10 to 200 micrograms per subject lengthened the duration of stimulated GH release.

    In plain wordsIn normal people, higher peptide doses made the growth hormone release last longer.

    Peptide
    Sermorelin
    Outcome
    IncreaseDuration of stimulated GH release with increasing dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10-200 micrograms per subjectAs given in this study (human).

    Source sentences

    Summary
    increasing doses from 10-200 micrograms per subject augments the duration of stimulated growth hormone (GH) release
    1 context sentence
    Summary · context
    Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normal subjects, peak serum GH showed only a poor correlation with the dose of GHRH(1-29)NH2.

    In plain wordsIn normal people, the highest growth hormone level was only weakly related to the peptide dose.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak serum GH versus dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10-200 micrograms per subjectAs given in this study (human).

    Source sentences

    Summary
    but the peak serum GH shows only a poor correlation with dose.
    1 context sentence
    Summary · context
    Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects.
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient patients, a poor GH response to GHRH was generally seen in those on long-term GH therapy.

    In plain wordsIn people with low growth hormone, those on long-term growth hormone treatment generally had a poor response to GHRH.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH response in patients on long-term GH therapy
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A poor response to GHRH was generally seen in patients on long-term GH therapy.
    1 context sentence
    Summary · context
    In 20 children and young adults with growth hormone deficiency by conventional criteria
  6. 06HumanNon-randomized trialEfficacy outcome

    In the study, priming with GHRH, as a single bolus or a continuous infusion, did not increase the GH response to GHRH.

    In plain wordsIn the study, giving GHRH beforehand, by injection or infusion, did not increase the growth hormone response to later GHRH.

    Peptide
    Sermorelin
    Outcome
    No significant changeEffect of GHRH priming on subsequent GH response
    Study

    n: not reported in source

    Comparator
    No priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Priming with GHRH, in either a single bolus or a continuous infusion, did not increase the GH response to GHRH.
    1 context sentence
    Summary · context
    In 20 children and young adults with growth hormone deficiency by conventional criteria

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.